The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper
Open accessAbstract
NSAID‐exacerbated respiratory disease (N‐ERD) is a chronic eosinophilic, inflammatory disorder of the respiratory tract occurring in patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRS w NP), symptoms of which are exacerbated by NSAID s, including aspirin. Despite some progress in understanding of the pathophysiology of the syndrome, which affects 1/10 of patients with asthma and rhinosinusitis, it remains a diagnostic and therapeutic challenge. In order to provide evidence‐based recommendations for the diagnosis and management of N‐ERD, a panel of international experts was called by the EAACI Asthma Section. The document summarizes current knowledge on the pathophysiology and clinical presentation of N‐ERD pointing at significant heterogeneity of this syndrome. Critically evaluating the usefulness of diagnostic tools available, the paper offers practical algorithm for the diagnosis of N‐ERD. Recommendations for the most effective management of a patient with N‐ERD stressing the potential high morbidity and severity of the underlying asthma and rhinosinusitis are discussed and proposed. Newly described sub‐phenotypes and emerging sub‐endotypes of N‐ERD are potentially relevant for new and more specific (eg, biological) treatment modalities. Finally, the document defines major gaps in our knowledge on N‐ERD and unmet needs, which should be addressed in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Self-citationChronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
Hastan, D., Fokkens, W. J., Bachert, C., Newson, R. B., Bislimovska, J., Bockelbrink, A., Bousquet, P. J., Brozek, G., Bruno, A., Dahlén, S. E., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02646.x · Cited by 1,112
Self-citationIntolerance to Aspirin: Clinical Studies and Consideration of its Pathogenesis
SAMTER, M., & BEERS, R. F. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-5-975 · Cited by 839
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · cited 1×
“Mepolizumab, an anti‐IL‐5 monoclonal antibody that has been approved for severe eosinophilic asthma, has been shown in two studies to decrease nasal polyposis,(60,71) and dupilumab, the IL‐4Rα antagonist that blocks both IL‐4 and IL‐13 signaling, has also been shown to decrease nasal polyps burden.(61) New biologicals…”
BackgroundSelf-citationThe ENFUMOSA Study Group (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00261903 · Cited by 759
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Natural history of aspirin-induced asthma
Szczeklik, A., Niżankowska, E., Duplaga, M., & the Aiane Investigators, O. B. O. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.016003432.x · Cited by 550
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Bachert, C., Sousa, A. R., Lund, V. J., Scadding, G. K., Gevaert, P., Nasser, S., Durham, S. R., Cornet, M. E., Kariyawasam, H. H., Gilbert, J., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.05.044 · Cited by 505
Self-citationKowalski, M. L., Asero, R., Bavbek, S., Blanca, M., Blanca‐Lopez, N., Bochenek, G., Brockow, K., Campo, P., Celik, G., Cernadas, J., et al. (2013) · Allergy · doi:10.1111/all.12260 · Cited by 499
Self-citationSzczeklik, A., Gryglewski, R. J., & Czerniawska-Mysik, G. (1975) · BMJ · doi:10.1136/bmj.1.5949.67 · Cited by 484
Cited by
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
Self-citationERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Dumonceau, J.-M., Kapral, C., Aabakken, L., Papanikolaou, I. S., Tringali, A., Vanbiervliet, G., Beyna, T., Dinis-Ribeiro, M., Hritz, I., Mariani, A., et al. (2020) · Endoscopy · doi:10.1055/a-1075-4080 · Cited by 934
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Gevaert, P., Omachi, T. A., Corren, J., Mullol, J., Han, J., Lee, S. E., Kaufman, D., Ligueros-Saylan, M., Howard, M., Zhu, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.032 · Cited by 739
Self-citationInternational consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Self-citationChronic Rhinosinusitis with Nasal Polyps and Asthma
Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N., & Mannent, L. P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.063 · Cited by 419
Self-citation
Metadata
- Authors
- Kowalski, M. L., Agache, I., Bavbek, S., Bakirtas, A., Blanca, M., Bochenek, G., Bonini, M., Heffler, E., Klimek, L., Laidlaw, T. M., Mullol, J., Niżankowska‐Mogilnicka, E., Park, H., Sanak, M., Sanchez‐Borges, M., Sanchez‐Garcia, S., Scadding, G., Taniguchi, M., Torres, M. J., White, A. A., & Wardzyńska, A.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2018-10-02
- Volume
- 74
- Issue
- 1
- Pages
- 28-39
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2891218618
- Cited by
- 360
- References
- 50
- FWCI
- 19.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper. https://app.cochat.ai/papers/10.1111/all.13599
- The paper
- Kowalski, M. L., Agache, I., Bavbek, S., Bakirtas, A., Blanca, M., Bochenek, G., Bonini, M., Heffler, E., Klimek, L., Laidlaw, T. M., Mullol, J., Niżankowska‐Mogilnicka, E., Park, H., Sanak, M., Sanchez‐Borges, M., Sanchez‐Garcia, S., Scadding, G., Taniguchi, M., Torres, M. J., . . . Wardzyńska, A. (2019). Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper. Allergy. https://doi.org/10.1111/all.13599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.